TCT-224 TIMI ≥ 2 in Right Ventricular Branches after Primary PCI, protects Right Ventricle against Infarction in the evaluation of Late Enhancement Cardiac Magnetic Resonance Imaging.  by Tomala, Marek T. et al.
Table 1. Characteristics of the study population overall and by stent type*
Overall (n=1,442) BMS (n=341) DES (n=1,101) p
Age (y) 64  13 65.6  14.9 63.1  12.0 0.002
Male 1,053 (73%) 217 (64%) 836 (76%) <0.001
Race 0.013
White 869 (60%) 214 (63%) 655 (59%)
Black 181 (13%) 54 (16%) 127 (12%)
Asian 241 (17%) 49 (14%) 192 (17%)
Other 151 (10%) 24 (7%) 127 (12%)
Hispanic 112 (8%) 31 (9%) 81 (7%) 0.273
Insurance 0.237
None/Military/State 103 (7%) 31 (9%) 72 (7%)
Medicare/Medicaid 257 (18%) 56 (16%) 201 (18%)
Private 1,082 (75%) 254 (74%) 828 (75%)
Smoking 362 (25%) 106 (31%) 256 (23%) 0.004
HTN 1,023 (71%) 248 (73%) 775 (71%) 0.432
Dyslipidemia 945 (66%) 208 (61%) 737 (67%) 0.037
Family Hx of CAD 189 (13%) 55 (16%) 134 (12%) 0.066
Prior MI 208 (14%) 56 (11%) 172 (16%) 0.019
Prior CHF 66 (5%) 28 (8%) 38 (3%) <0.001
Prior valve surgery 21 (1%) 12 (4%) 9 (1%) <0.001
Prior PCI 320 (22%) 68 (20%) 252 (23%) 0.237
Prior CABG 71 (5%) 30 (9%) 41 (4%) <0.001
Dialysis 15 (1%) 3 (1%) 12 (1%) 0.740
Prior CVD 78 (5%) 26 (8%) 52 (5%) 0.039
Prior PAD 60 (4%) 37 (11%) 23 (2%) <0.001
Chronic lung disease 49 (3%) 28 (8%) 21 (2%) <0.001
Diabetes 433 (30%) 84 (25%) 349 (32%) 0.013
Anti-anginal medication 584 (41%) 147 (43%) 437 (40%) 0.261
Beta blockers 418 (72%) 104 (71%) 314 (72%) 0.797
Calcium channel blockers 265 (45%) 83 (56%) 182 (42%) 0.002
Long-acting nitrates 104 (18%) 20 (14%) 84 (19%) 0.124
Ranolazine 5 (1%) 0 (0%) 5 (1%) 0.338
Femoral access 1,317 (91%) 317 (93%) 1,000 (91%) 0.221
In-Stent Restenosisy 54 (56%) 10 (40%) 45 (62%) 0.067
Stent Thrombosisy 69 (70%) 23 (92%) 46 (63%) 0.006
Vessels involved
Left main 25 (2%) 6 (2%) 19 (2%) 0.967
LAD 805 (56%) 161 (47%) 644 (58%) <0.001
LCx 517 (36%) 116 (34%) 401 (36%) 0.419
RCA 856 (59%) 221 (65%) 635 (58%) 0.020
Ramus 33 (2%) 5 (1%) 28 (3%) 0.304
LAD graft 13 (1%) 6 (2%) 7 (1%) 0.055
LCx graft 43 (3%) 24 (7%) 19 (2%) <0.001
RCA graft 25 (2%) 12 (4%) 13 (1%) 0.007
Ramus graft 0 (0%) 0 (0%) 0 (0%) 1.000
Vessel diameter (mm) 2.9  0.5 3.1  0.6 2.9  0.4 <0.001
Lesion length (mm) 27.0  15.4 28.1  18.0 26.6  14.5 0.120
Stent length (mm) 19.8  6.3 18.9  5.6 20.0  6.4 0.004
Adverse outcome 157 (11%) 79 (23%) 78 (7%) <0.001
Dissection 21 (2%) 9 (3%) 12 (1%) 0.037
Perforation 8 (1%) 1 (1%) 7 (1%) 0.689
Myocardial infarction 8 (1%) 0 (0%) 8 (1%) 0.210
CVA 2 (1%) 1 (1%) 1 (1%) 0.418
Transfusion 105 (7%) 60 (18%) 45 (4%) <0.001
Bleeding 43 (3%) 33 (10%) 10 (1%) <0.001
CABG 1 (1%) 1 (1%) 0 (0%) 0.236
Death 30 (2%) 25 (7%) 5 (1%) <0.001
HTN ¼ Hypertension.
Discrete variables are provided as frequency (%).
Continuous variables are provided as mean  standard deviation.
*n ¼ 1,442.
yn ¼ 98.
Table 2. End points by stent type across divides of interest*
BMS (n = 341) DES (n = 1,101) p
Female
Death 18 (15%) 2 (1%) <0.001
Adverse outcome 40 (32%) 13 (5%) <0.001
Male
Death 7 (3%) 3 (1%) <0.001
Adverse outcome 39 (18%) 65 (8%) <0.001
Non Hispanic
Death 19 (6%) 5 (1%) <0.001
Adverse outcome 70 (23%) 64 (6%) <0.001
Hispanic
Death 6 (19%) 0 (0%) <0.001
Adverse outcome 7 (23%) 2 (2%) <0.001
White
Death 20 (9%) 5 (1%) <0.001
Adverse outcome 52 (24%) 48 (7%) <0.001
Black
Death 0 (0%) 0 (0%) 1.000
Adverse outcome 20 (37%) 5 (4%) <0.001
Asian
Death 5 (10%) 0 (0%) <0.001
Adverse outcome 6 (12%) 12 (6%) 0.154
Other
Death 0 (0%) 0 (0%) 1.000
Adverse outcome 1 (4%) 13 (10%) 0.347
None/Military/State
Death 1 (3%) 2 (3%) 0.901
Adverse outcome 1 (3%) 2 (3%) 0.901
Private
Death 13 (5%) 3 (1%) <0.001
Adverse outcome 64 (25%) 66 (8%) <0.001
Medicare/Medicaid
Death 11 (20%) 0 (0%) <0.001
Adverse outcome 14 (25%) 10 (5%) <0.001
*End points reported as frequency since unadjusted and adjusted odds ratios frequently
showed perfect prediction of outcome. When numerical odds ratios were available the results
were similar to the reported frequencies.
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patients undergoing PCI highlighting a bias in our practice. Except for patients with
the most limited insurance status all subjects showed better outcomes with DES which
should be considered as the preferred option in STEMI patients.
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Background: Right ventricular (RV) infarction (RVI) is associated with an unfa-
vorable prognosis, however there is a paucity of data regarding the factors which are
the real causes of the RVI. This study was designed to determine the impact of
primary percutaneous coronary intervention effect on the presence of RVI evaluated
by late enhancement cardiovascular magnetic resonance.
Methods: We prospectively assessed the association between the ﬂow in major
(1 mm) RV branches before and after primary PCI of Right Coronary Artery (RCA)
in 114 patients with the ﬁrst acute inferior myocardial infarction. In 3-5 days after
coronary reperfusion with PCI, cardiovascular magnetic resonance was performed for
assessing the presence of late enhancement in the RV wall.
Results: The only two angiographical factors that caused the presence of RV
infarction were TIMI<2 ﬂow in at least one RV branch (odds ratio 143; 95 percent
conﬁdence interval 18.1 to 1130.0; p <0.001), and distal embolization of posterioracts/POSTER/STEMI/NSTEMI/ACS B73
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<0.001) after primary PCI.
Conclusions: Restoration of TIMI ﬂow  2 in all major RV branches during primary
percutaneous coronary intervention, as well as the absence of distal embolization of
the posterior descendent artery, results in lack of cardiovascular magnetic resonance
late enhancement in the right ventricular wall after procedure, regardless of initial
angiographic status.Parameter OR 95% CI p
3-vessel disease 0,433 0,193-0,974 0,043
EF < 50% 0,377 0,160-0,888 0,026
Age > 75 years 0,29 0,114-0,740 0,01
Renal failure 0,259 0,100-0,675 0,006
LM culprit vessel 0,062 0,006-0,601 0,016TCT-225
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Background: The SYNTAX score (SS) has demonstrated strong prognostic utility for
ischemic outcomes in patients undergoing PCI for stable ischemic disease, non-ST-
segment elevation acute coronary syndromes (NSTEACS), and STEMI. We sought to
determine the relationship between the SS and bleeding risk in patients undergoing
percutaneous coronary intervention (PCI) for NSTEACS.
Methods: We stratiﬁed 2,627 patients from the ACUITY in whom PCI was per-
formed into SS groups based on score tertiles (SS <7, 7-12, and >12). Thirty-day
major bleeding rates were determined for each group.
Results: As demonstrated in the Figure, 30-day major bleeding rates were signiﬁ-
cantly greater in the highest SS tertile (>12) compared with intermediate (7-12) and
lowest (<7) tertiles. By multivariable analysis, the SS was independently associated
with 30-day major bleeding (HR per 1 SS point: 1.03, 95% CI: 1.01 to 1.04;
p¼0.003).
Conclusions: In the large-scale ACUITY trial, in addition to its previously described
prognostic utility for adverse ischemic events, the SS was independently associated
with major bleeding after PCI for NSTEACS.TCT-226
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Background: Renal failure (RF) is associated with increased cardiovascular mortality
in patients with acute coronary syndromes (ACS). Nevertheless patients with RF are
less likely to receive reperfusion therapy during AMI. This study is the ﬁrst reportB74 JACC Vol 62/18/Suppl B j October 2from a contemporary randomized controlled trial (RCT) addressing the impact of RF
on long-term clinical outcomes in patients undergoing primary PCI for AMI.
Methods: 745 patients with STEMI underwent primary PCI were enrolled in this
study and were divided in two groups according with the baseline estimated creatinine
clearance (calculated by the use of the Cockcroft-Gault formula) and the National
Kidney Foundation criteria (group A: 176 patients, class III-IV-V; group B: 569
patients, class I-II).
Results: Multivariate logistic regression shows a signiﬁcantly correlation of RF with
3-years cardiovascular death (Table 1). Kaplan-Meier analysis show a signiﬁcantly
decreased of the event-free survival curves for 3-years CV death (log rank <0,001,
Figure 1) in patients with RF.Conclusions: RF is signiﬁcantly associated with 3-years CV death in patients with
AMI treated with successful primary PCI despite no differences in term of treatment
between patients with or without RF.
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Background: Although PPCI has become the preferring reperfusion modality for
STEMI nowadays, thrombolysis remains useful when PPCI will be remarkably
delayed, which is still common in real practice. However, there’re concerns on the
weakness of single thrombolysis, especially re-occlusion of the vessel. It has been
suggested that early PCI after thrombolysis might improve its efﬁcacy. We used CMR
to further investigate this “pharmacoinvasion” strategy.
Methods: Current data came from an ongoing RCT comparing pharmacoinvasion and
PPCI for STMEI within 12h. Pharmacoinvasion was composed of r-TPA thrombolysis
and angiography/PCI 3-24h thereafter except for thrombolysis failure, in which
situation a rescue PCI would be done immediately. CMR was performed 2-8d after
reperfusion.
Results: 51 in pharmacoinvasion and 49 patients in PPCI group received CMR assay,
representing 80.1% of total patients. Rate of successful thrombolysis was 84.4%
(TIMI ﬂow grades2 in culprit artery). Median time between thrombolysis and
angiography was 7.7h (3.6 to 16.5h). 49 in pharmacoinvasion and all patients in PPCI
group received stenting. Symptom-to-CMR time and other baseline characteristics
were similar except for door-to-reperfusion time (door-to-needle/door-to-balloon time
for thrombolysis/PPCI), which was signiﬁcantly shorter in pharmacoinvasion group
(4422min vs. 8641min, p<0.001). Most of the CMR results were statistically
equal between pharmacoinvasion and PPCI arms: LVEF 52.210.7% vs. 4911.7%,
p¼0.167; Intramyocardial hemorrhage 43.1% vs. 48.9%, p¼0.548; Microvascular
obstruction (MVO) 64.7% vs. 65.3%, p¼1.000; MVO size (proportion to LV
myocardium) 2.02.8% vs. 2.12.9%, p¼0.818. However, infarction size (pro-
portion to LV myocardium) was signiﬁcantly lower in pharmacoinvasion group:
23.512.3% vs. 29.716.2%, p¼0.034.
Conclusions: Current CMR data suggested that pharmacoinvasion strategy may have
comparable efﬁcacy as PPCI. Much shorter door-to-reperfusion time showing in this7–November 1, 2013 j TCT Abstracts/POSTER/STEMI/NSTEMI/ACS
